EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity

Cintia A Menendez, Adil Mohamed, Gustavo R Perez-Lemus iD, Adam M Weiss iD, Benjamin W Rawe, Guancen Liu, Alex E Crolais, Emma Kenna iD, Fabian Byléhn iD, Walter Alvarado, Dan Mendels, Stuart J Rowan and 2 more

Molecules · 2023

DOI: 10.3390/molecules28186643 ↗

At a glance

Journal article in Molecules, 2023. Written by Cintia A Menendez and 13 co-authors. Institution: Pritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA. Major MEDLINE topics: Piperidines, Benzamides, Pyridines. Cited 2 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIGMS NIH HHS, Department of Energy, Office of Science.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Recently, a high-throughput screen of 1900 clinically used drugs identified masitinib, an orally bioavailable tyrosine kinase inhibitor, as a potential treatment for COVID-19. Masitinib acts as a broad-spectrum inhibitor for human coronaviruses, including SARS-CoV-2 and several of its variants. In this work, we rely on atomistic molecular dynamics simulations with advanced sampling methods to develop a deeper understanding of masitinib’s mechanism of Mpro inhibition. To improve the inhibitory efficiency and to increase the ligand selectivity for the viral target, we determined the minimal portion of the molecule (fragment) that is responsible for most of the interactions that arise within the masitinib-Mpro complex. We found that masitinib forms highly stable and specific H-bond interactions with Mpro through its pyridine and aminothiazole rings. Importantly, the interaction with His163 is a key anchoring point of the inhibitor, and its perturbation leads to ligand unbinding within nanoseconds. Based on these observations, a small library of rationally designed masitinib derivatives (M1–M5) was proposed. Our results show increased inhibitory efficiency and highly reduced cytotoxicity for the M3 and M4 derivatives compared to masitinib.

Subjects

MeSH terms (MEDLINE)

PiperidinesBenzamidesPyridinesHumansLigandsThiazolesAntiviral AgentsProtease Inhibitors

Author keywords

Mpro inhibitorsSARS-CoV-2masitinib derivatives

Substances

masitinibLigandsPiperidinesBenzamidesThiazolesAntiviral AgentsProtease InhibitorsPyridines

Authors and institutions

  • Pritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.
  • Department of Chemistry, University of Chicago, 5735 South Ellis Avenue, Chicago, IL 60637, USA.
  • Argonne National Laboratory, 9700 South Cass Avenue, Lemont, IL 60439, USA.

ORCID profiles: Gustavo R Perez-Lemus, Adam M Weiss, Emma Kenna, Fabian Byléhn

Funding

  • NIGMS NIH HHS
  • Department of Energy
  • Office of Science
  • Basic Energy Sciences
  • Division of Materials Science and Engineering
  • NSF
  • NIH Chemistry-Biology Interface training

Cite

APA

Menendez, C. A., Mohamed, A., Perez-Lemus, G. R., Weiss, A. M., Rawe, B. W., Liu, G., Crolais, A. E., Kenna, E., Byléhn, F., Alvarado, W., Mendels, D., Rowan, S. J., Tay, S., & de Pablo, J. J. (2023). Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules. https://doi.org/10.3390/molecules28186643

Vancouver

Menendez CA, Mohamed A, Perez-Lemus GR, Weiss AM, Rawe BW, Liu G, et al. Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules. 2023. doi:10.3390/molecules28186643

BibTeX
@article{Menendez2023,
  author = {Menendez, Cintia A and Mohamed, Adil and Perez-Lemus, Gustavo R and Weiss, Adam M and Rawe, Benjamin W and Liu, Guancen and Crolais, Alex E and Kenna, Emma and Byléhn, Fabian and Alvarado, Walter and Mendels, Dan and Rowan, Stuart J and Tay, Savaş and de Pablo, Juan J},
  title = {Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28186643}
}
Start for free →